Healthcare AI Adoption — Global Regulatory Patchwork
OVERVIEWPYMNTS.com analysis highlights that healthcare AI adoption is running into a fragmented global regulatory environment, with different jurisdictions applying incompatible frameworks to the same AI tools and creating compliance complexity for vendors and health systems operating across borders. The EU AI Act, US FDA device regulation, UK MHRA guidance, and emerging frameworks in South Korea, India, and other markets each impose different requirements for AI clinical tools — creating a patchwork that increases the cost and complexity of international AI healthcare deployment. For multinational health technology companies, the regulatory patchwork means that a single AI product may require separate regulatory submissions, clinical evidence packages, and post-market surveillance systems in each jurisdiction where it is deployed. This creates barriers to entry for smaller AI vendors and may concentrate the international market among large technology companies with the regulatory infrastructure to navigate multiple frameworks simultaneously. The patchwork also creates arbitrage risks: AI tools that cannot meet stringent regulatory requirements in one jurisdiction may be deployed in markets with lighter oversight, creating equity concerns about which patient populations bear the risks of less rigorously evaluated AI. The PYMNTS analysis frames regulatory harmonization — or at minimum, mutual recognition agreements between major jurisdictions — as a necessary condition for responsible…
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.